Nu Skin Enterprises, Inc.

are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand over the conference to your first speaker today, B.G. Hunt, Vice President, Treasurer, and Investor Relations. Please go ahead.

Thanks, Danielle. And good afternoon, everyone. I'm joined by Ryan Napierski, President and CEO, and James Thomas, CFO. We're excited to share Nu Skin's results from Q3 of 2025. Before I turn time over to Ryan, let me point out that on today's call, comments will be made that include forward-looking statements. These statements involve important risks and uncertainties, and actual results may differ materially from those discussed or anticipated. Please refer today's earnings release and our SEC filings for a complete discussion of these risks. Also during the call, certain financial numbers may be discussed that differ from comparable numbers obtained in our financial statements. We believe these non-GAAP numbers assist in comparing period to period results in a more consistent manner. please refer to our investor website, ir.newskin.com, for any required reconciliation of these non-GAAP numbers. And with that, I'd like to now turn the call over to Ryan.

Thanks, BG. Thanks, everybody, for joining the call today. I'm pleased to report that we delivered third quarter revenue of $364 million, which was within our guidance range. We also delivered EPS of $0.34 at the higher end of our guidance range, And I'm encouraged by our ability to maintain disciplined execution amidst ongoing macro environmental pressures that are impacting the industry. With three quarters behind us, we are now focused on Q4 as we further our vision of becoming the world's leading intelligent beauty, wellness, and lifestyle leadership opportunity platform by preparing for our next big opportunities with the introduction of Prism.io, our truly intelligent wellness platform, and the pre-market opening of India, which I'll come back to in just a few minutes. Latin America continued its exceptional growth trajectory up 53% year over year. This is demonstrating the potential of our emerging market strategy, which is enabling us to reach a broader, aspiring middle target market of entrepreneurs and customers. This growth was offset by continued challenges in North America, where we have been transforming our business model to address macro-environmental landscape matters. However, I'm pleased to report sequential growth in Europe and Africa, South Korea, Southeast Asia Pacific, and Hong Kong and Taiwan. In mainland China, we're seeing improving trends as well across our KPIs as we introduced our TrueFace clinically-backed skincare line, and our Rise segment performed as anticipated with LifeDNA exceeding expectations. Now, I'll return to our strategic priorities that we outlined for the year. Our top priority for the core Nu Skin business is to ignite the passion and energy of our highly committed and dedicated sales leaders with our next big opportunities. First, the introduction of Prism IO, our truly intelligent wellness platform, and second, the expansion of our emerging market strategy into India as we seek to extend the Nu Skin opportunity to this exciting market. Our teams and sales leaders around the globe have been laying the groundwork for these two key introductions over the past few years, and we're excited to initiate both of them in a limited fashion this quarter with full-scale launches in 2026. Let me first share some updates on Prism IO that include our proprietary health assessment device paired with our AI-powered Intelligent Insights app that helps consumers navigate their personal wellness journey. While premium beauty continues to be under pressure, the wellness industry and specifically the intelligent wellness market is expanding dramatically. And new entrants are rapidly expanding awareness about the importance of intelligent health and measuring biomarkers. According to Grandview Research, the intelligent wellness wearables market has been growing by double digits and reached $84 billion in 2024, as consumers desire greater insights into their overall well-being by measuring and tracking their internal biomarkers. And the total addressable market for nutritional supplements reached nearly $500 billion in 2024, and is expected to grow to over $700 billion by 2030, with very little ability to know whether these supplements actually work. NuSkin is already regarded as the world's number one beauty device systems brand, according to Euromonitor, which is becoming an even greater strategic advantage within the beauty and wellness industries. Additionally, we hold more than 40 years of science-backed research and development in this space, and more than 20 years of intelligent wellness research contained in our biophotonic scanner. including insights and trends from the aggregate of 21 million scans from more than 10 million people across more than 50 countries around the world. Combined, these competitive advantages place us in a very unique position to introduce PRISM-IO, an entirely new non-invasive device that measures one's skin carotenoid levels, providing people with valuable insights into their antioxidant status and nutritional health. With the rapid acceleration of a genetic AI, we're training our own proprietary language model, which will enable us to derive deep, actionable insights about our consumers' overall wellness and expand our ability to service customers as they navigate their personal wellness journey. Prism.io and our Intelligent Wellness app provide personalized nutritional insights across the broader wellness journey, covering one's diet, fitness, oxidative stress and sleep, and nutritional supplementation, and generates personalized product solution recommendations. From a scalability perspective, this more portable form factor, ability to scan quickly, and more accessible price point for PRISM-IO will enable us to place significantly more devices around the globe. We currently have approximately 1,500 biophotonic scanners in the field today, and we anticipate placing more than 10,000 Prism IO units in Q4, with tens of thousands of units placed per quarter throughout 2026. From a business building perspective, the unit economics of Prism IO are also incredibly compelling, as our experience has shown that more customers being scanned leads directly to more subscriptions. Subscribed customers produce approximately seven times greater lifetime value than non-subscribed customers, and we have more than 300,000 subscribed customers in any given month on our platform. We believe that Prism.io will enable us to significantly expand our subscribed customer base in the coming years, which will further strengthen our Salesforce productivity as they lean in to drive this truly intelligent wellness movement around the world. Q4 sets the foundation for limited Prism.io brand representative previews, And in early 2026, we will begin opening up sales via our sales leaders to their affiliates and customers. Full consumer launches are currently scheduled for the second half of the year. Our second strategic priority focuses on expanding our emerging market business model into India. With 1.4 billion people, India is one of the largest future opportunities for us globally. where there is a rapidly growing middle class segment of the market who need what we offer to look, feel, and live more empowered lives. We are entering India with a more focused and scalable business model based on our learnings in Latin America, which include a localized product portfolio, price for India's growing middle class, a refined compensation plan, and a digital-first infrastructure with our India-based Infosys partners. We recently hired a dynamic local management team, and I'm excited to be kicking off our qualified pre-market opening beginning next week with a multi-city tour across India, working towards our full-scale opening anticipated in the back half of next year. I'm excited about the potential for India and our other emerging markets, which we anticipate will become a much larger part of our core business revenue in the coming years. Paired with these two exciting top-line growth drivers, we remain focused on continuing to strengthen our financial performance and profitability across the business as we sustainably grow gross margin by optimizing our product portfolio, manage selling expense to ensure optimal rewards for our hardworking sales force, and drive overall profitability across our business segments around the globe. We believe these initiatives will continue to strengthen our overall financial position and improve shareholder value in the quarters and years to come. So with that, I'll turn the time over to James to dive deeper into our financial performance and outlook for the remainder of the year. James.